RxDoctor Payments Data

James Holton, MD

Internal Medicine · Medford, NJNPI 1740215938

Payments from drug & device makers

$44,635in general payments, 2019–2025

Across 527 payments — averaging $84.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$39K
  • AstraZeneca$965
  • GSK$791
  • Amarin Pharma, Inc.$594
  • Kowa Pharmaceuticals America, Inc.$411
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$337
  • plus $2K from 34 others

What the payments were for

  • Speaking & faculty fees$36,53882%
  • Travel & lodging$8682%
  • Food & beverage$7,22916%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,635 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$105,084
Medicare patients
423
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$166,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$71,786
JardianceEmpagliflozin65$69,685
TrulicityDulaglutide51$59,724
MounjaroTirzepatide45$54,610
XareltoRivaroxaban32$50,308
OzempicSemaglutide31$45,353
Repatha SureclickEvolocumab32$29,943
JanuviaSitagliptin Phosphate18$24,687
Pitavastatin Calcium33$17,767
Breo ElliptaFluticasone/Vilanterol21$17,555
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$16,839
VascepaIcosapent Ethyl28$14,824
InvokanaCanagliflozin13$13,618
EntrestoSacubitril/Valsartan19$12,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$265$166,621146 claims
Lilly USA, LLCTrulicity, Mounjaro$250$114,33496 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$791$106,179111 claims
Boehringer IngelheimJardiance$68$69,68565 claims
Johnson & JohnsonXarelto, Invokana$97$63,92645 claims
Novo NordiskOzempic$293$45,35331 claims
MerckJanuvia$119$24,68718 claims
AbbVieLinzess, Synthroid$39,142$13,58075 claims
NovartisEntresto$148$12,34919 claims
AstraZenecaBreztri Aerosphere$965$12,09811 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$337$11,21411 claims
Astellas Pharma US IncMyrbetriq$27$10,88219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Medford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →